|     | AA_match                                                        |    af | disease                               | drugs                                            |
|----:|:----------------------------------------------------------------|------:|:--------------------------------------|:-------------------------------------------------|
|   0 | NRAS:NM_002524:exon3:c.C181A:p.Q61K                             | 0.017 | Neuroblastoma                         | Binimetinib,Everolimus                           |
|   1 | NRAS:NM_002524:exon3:c.C181A:p.Q61K                             | 0.017 | Skin Melanoma                         | Vemurafenib                                      |
|   2 | NRAS:NM_002524:exon3:c.C181A:p.Q61K                             | 0.017 | Skin Melanoma                         | Selumetinib                                      |
|   3 | NRAS:NM_002524:exon3:c.C181A:p.Q61K                             | 0.017 | Colorectal Cancer                     | Chemotherapy,Cetuximab                           |
|   4 | NRAS:NM_002524:exon3:c.C181A:p.Q61K                             | 0.017 | Colorectal Cancer                     | Dactolisib,Selumetinib                           |
|   5 | NRAS:NM_002524:exon3:c.C181A:p.Q61K                             | 0.017 | Lung Non-small Cell Carcinoma         | Trametinib,Selumetinib                           |
|   6 | NRAS:NM_002524:exon3:c.C181A:p.Q61K                             | 0.017 | Ovary Serous Adenocarcinoma           | Trametinib                                       |
|   7 | PIK3CA:NM_006218:exon2:c.G333C:p.K111N                          | 0.027 | Her2-receptor Positive Breast Cancer  | Pictilisib                                       |
|   8 | PIK3CA:NM_006218:exon2:c.G333C:p.K111N                          | 0.027 | Her2-receptor Positive Breast Cancer  | Trastuzumab Emtansine                            |
|   9 | PIK3CA:NM_006218:exon2:c.G333C:p.K111N                          | 0.027 | Her2-receptor Positive Breast Cancer  | PI-103                                           |
|  10 | PIK3CA:NM_006218:exon2:c.G333C:p.K111N                          | 0.027 | Her2-receptor Positive Breast Cancer  | PI3Ka/Di                                         |
|  11 | PIK3CA:NM_006218:exon2:c.G333C:p.K111N                          | 0.027 | Her2-receptor Positive Breast Cancer  | Trastuzumab,Dactolisib,Lapatinib                 |
|  12 | PIK3CA:NM_006218:exon2:c.G333C:p.K111N                          | 0.027 | Her2-receptor Positive Breast Cancer  | Trastuzumab                                      |
|  13 | PIK3CA:NM_006218:exon21:c.A3140G:p.H1047R                       | 0.03  | Colorectal Cancer                     | Cetuximab,Panitumumab                            |
|  14 | PIK3CA:NM_006218:exon21:c.A3140G:p.H1047R                       | 0.03  | Breast Cancer                         | PI3K-alpha Inhibitor MEN1611                     |
|  15 | PIK3CA:NM_006218:exon21:c.A3140G:p.H1047R                       | 0.03  | Colorectal Cancer                     | Cetuximab,Panitumumab                            |
|  16 | PIK3CA:NM_006218:exon21:c.A3140G:p.H1047R                       | 0.03  | Head And Neck Cancer                  | Dactolisib                                       |
|  17 | PIK3CA:NM_006218:exon21:c.A3140G:p.H1047R                       | 0.03  | Head And Neck Cancer                  | Dactolisib                                       |
|  18 | PIK3CA:NM_006218:exon21:c.A3140G:p.H1047R                       | 0.03  | Head And Neck Cancer                  | Cetuximab,Dactolisib                             |
|  19 | PIK3CA:NM_006218:exon21:c.A3140G:p.H1047R                       | 0.03  | Head And Neck Cancer                  | Alpelisib                                        |
|  20 | PIK3CA:NM_006218:exon21:c.A3140G:p.H1047R                       | 0.03  | Lung Adenocarcinoma                   | Dactolisib                                       |
|  21 | PIK3CA:NM_006218:exon21:c.A3140G:p.H1047R                       | 0.03  | Head And Neck Squamous Cell Carcinoma | Taselisib                                        |
|  22 | PIK3CA:NM_006218:exon21:c.A3140G:p.H1047R                       | 0.03  | Her2-receptor Positive Breast Cancer  | Trastuzumab,Capivasertib                         |
|  23 | PIK3CA:NM_006218:exon21:c.A3140G:p.H1047R                       | 0.03  | Her2-receptor Positive Breast Cancer  | Lapatinib,Capivasertib                           |
|  24 | PIK3CA:NM_006218:exon21:c.A3140G:p.H1047R                       | 0.03  | Her2-receptor Positive Breast Cancer  | Everolimus,Fulvestrant                           |
|  25 | PIK3CA:NM_006218:exon21:c.A3140G:p.H1047R                       | 0.03  | Thyroid Gland Cancer                  | Temsirolimus,Perifosine                          |
|  26 | PIK3CA:NM_006218:exon21:c.A3140G:p.H1047R                       | 0.03  | Her2-receptor Positive Breast Cancer  | Pictilisib                                       |
|  27 | PIK3CA:NM_006218:exon21:c.A3140G:p.H1047R                       | 0.03  | Breast Cancer                         | Pictilisib                                       |
|  28 | PIK3CA:NM_006218:exon21:c.A3140G:p.H1047R                       | 0.03  | Her2-receptor Positive Breast Cancer  | Trastuzumab Emtansine                            |
|  29 | PIK3CA:NM_006218:exon21:c.A3140G:p.H1047R                       | 0.03  | Colorectal Cancer                     | Vemurafenib                                      |
|  30 | PIK3CA:NM_006218:exon21:c.A3140G:p.H1047R                       | 0.03  | Colorectal Cancer                     | Cetuximab,Irinotecan                             |
|  31 | PIK3CA:NM_006218:exon21:c.A3140G:p.H1047R                       | 0.03  | Her2-receptor Positive Breast Cancer  | Trastuzumab,Lapatinib                            |
|  32 | PIK3CA:NM_006218:exon21:c.A3140G:p.H1047R                       | 0.03  | Her2-receptor Positive Breast Cancer  | Dactolisib                                       |
|  33 | PIK3CA:NM_006218:exon21:c.A3140G:p.H1047R                       | 0.03  | Colorectal Cancer                     | Vemurafenib,Akt Inhibitor MK2206                 |
|  34 | PIK3CA:NM_006218:exon21:c.A3140G:p.H1047R                       | 0.03  | Her2-receptor Positive Breast Cancer  | Trastuzumab                                      |
|  35 | KIT:NM_000222:exon17:c.A2447T:p.D816V                           | 0.021 | Systemic Mastocytosis                 | Midostaurin                                      |
|  36 | KIT:NM_000222:exon17:c.A2447T:p.D816V                           | 0.021 | Cancer                                | Imatinib                                         |
|  37 | KIT:NM_000222:exon17:c.A2447T:p.D816V                           | 0.021 | Cancer                                | Dasatinib,Imatinib                               |
|  38 | EGFR:NM_005228:exon18:c.G2155A:p.G719S                          | 0.061 | Lung Non-small Cell Carcinoma         | Gefitinib                                        |
|  39 | EGFR:NM_005228:exon18:c.G2155A:p.G719S                          | 0.061 | Colorectal Cancer                     | Cetuximab                                        |
|  40 | EGFR:NM_005228:exon18:c.G2155A:p.G719S                          | 0.061 | Lung Non-small Cell Carcinoma         | Erlotinib,Gefitinib                              |
|  41 | EGFR:NM_005228:exon18:c.G2155A:p.G719S                          | 0.061 | Lung Non-small Cell Carcinoma         | Erlotinib                                        |
|  42 | EGFR:NM_005228:exon19:c.2235_2249del:p.E746_A750del             | 0.011 | Bronchiolo-alveolar Adenocarcinoma    | Erlotinib                                        |
|  43 | EGFR:NM_005228:exon19:c.2235_2249del:p.E746_A750del             | 0.011 | Lung Non-small Cell Carcinoma         | Gefitinib                                        |
|  44 | EGFR:NM_005228:exon19:c.2235_2249del:p.E746_A750del             | 0.011 | Lung Non-small Cell Carcinoma         | Gefitinib                                        |
|  45 | EGFR:NM_005228:exon20:c.2296_2297insTGGCCAGCG:p.V769_D770insASV | 0.02  | Lung Adenocarcinoma                   | Erlotinib                                        |
|  46 | EGFR:NM_005228:exon20:c.C2369T:p.T790M                          | 0.019 | Lung Non-small Cell Carcinoma         | Erlotinib                                        |
|  47 | EGFR:NM_005228:exon20:c.C2369T:p.T790M                          | 0.019 | Lung Non-small Cell Carcinoma         | Gefitinib                                        |
|  48 | EGFR:NM_005228:exon20:c.C2369T:p.T790M                          | 0.019 | Lung Non-small Cell Carcinoma         | Dacomitinib                                      |
|  49 | EGFR:NM_005228:exon20:c.C2369T:p.T790M                          | 0.019 | Lung Non-small Cell Carcinoma         | Erlotinib,Pemetrexed                             |
|  50 | EGFR:NM_005228:exon20:c.C2369T:p.T790M                          | 0.019 | Lung Non-small Cell Carcinoma         | Staurosporine                                    |
|  51 | EGFR:NM_005228:exon20:c.C2369T:p.T790M                          | 0.019 | Lung Cancer                           | Gefitinib,Multikinase Inhibitor AEE788           |
|  52 | EGFR:NM_005228:exon20:c.C2369T:p.T790M                          | 0.019 | Lung Non-small Cell Carcinoma         | Rociletinib                                      |
|  53 | EGFR:NM_005228:exon20:c.C2369T:p.T790M                          | 0.019 | Lung Non-small Cell Carcinoma         | Rociletinib                                      |
|  54 | EGFR:NM_005228:exon20:c.C2369T:p.T790M                          | 0.019 | Lung Non-small Cell Carcinoma         | Osimertinib                                      |
|  55 | EGFR:NM_005228:exon20:c.C2369T:p.T790M                          | 0.019 | Lung Non-small Cell Carcinoma         | Osimertinib                                      |
|  56 | EGFR:NM_005228:exon20:c.C2369T:p.T790M                          | 0.019 | Lung Non-small Cell Carcinoma         | Osimertinib                                      |
|  57 | EGFR:NM_005228:exon20:c.C2369T:p.T790M                          | 0.019 | Lung Non-small Cell Carcinoma         | Osimertinib,Rociletinib                          |
|  58 | EGFR:NM_005228:exon20:c.C2369T:p.T790M                          | 0.019 | Lung Adenocarcinoma                   | Gefitinib,Erlotinib                              |
|  59 | EGFR:NM_005228:exon20:c.C2369T:p.T790M                          | 0.019 | Lung Adenocarcinoma                   | Osimertinib                                      |
|  60 | EGFR:NM_005228:exon20:c.C2369T:p.T790M                          | 0.019 | Lung Non-small Cell Carcinoma         | Osimertinib                                      |
|  61 | EGFR:NM_005228:exon20:c.C2369T:p.T790M                          | 0.019 | Lung Non-small Cell Carcinoma         | Gefitinib,Erlotinib                              |
|  62 | EGFR:NM_005228:exon20:c.C2369T:p.T790M                          | 0.019 | Lung Non-small Cell Carcinoma         | Afatinib                                         |
|  63 | EGFR:NM_005228:exon20:c.C2369T:p.T790M                          | 0.019 | Lung Non-small Cell Carcinoma         | Osimertinib                                      |
|  64 | EGFR:NM_005228:exon20:c.C2369T:p.T790M                          | 0.019 | Lung Adenocarcinoma                   | Osimertinib                                      |
|  65 | EGFR:NM_005228:exon20:c.C2369T:p.T790M                          | 0.019 | Lung Non-small Cell Carcinoma         | Gefitinib,Erlotinib                              |
|  66 | EGFR:NM_005228:exon20:c.C2369T:p.T790M                          | 0.019 | Lung Non-small Cell Carcinoma         | Gefitinib                                        |
|  67 | EGFR:NM_005228:exon20:c.C2369T:p.T790M                          | 0.019 | Lung Non-small Cell Carcinoma         | Lapatinib                                        |
|  68 | EGFR:NM_005228:exon20:c.C2369T:p.T790M                          | 0.019 | Lung Non-small Cell Carcinoma         | Dacomitinib                                      |
|  69 | EGFR:NM_005228:exon20:c.C2369T:p.T790M                          | 0.019 | Lung Non-small Cell Carcinoma         | Neratinib                                        |
|  70 | EGFR:NM_005228:exon20:c.C2369T:p.T790M                          | 0.019 | Lung Non-small Cell Carcinoma         | Afatinib                                         |
|  71 | EGFR:NM_005228:exon20:c.C2369T:p.T790M                          | 0.019 | Lung Non-small Cell Carcinoma         | Afatinib                                         |
|  72 | EGFR:NM_005228:exon20:c.C2369T:p.T790M                          | 0.019 | Lung Non-small Cell Carcinoma         | Canertinib                                       |
|  73 | EGFR:NM_005228:exon20:c.C2369T:p.T790M                          | 0.019 | Cancer                                | Gefitinib,Erlotinib,Multikinase Inhibitor AEE788 |
|  74 | EGFR:NM_005228:exon20:c.C2369T:p.T790M                          | 0.019 | Pancreatic Adenocarcinoma             | Osimertinib                                      |
|  75 | EGFR:NM_005228:exon21:c.T2573G:p.L858R                          | 0.012 | Lung Non-small Cell Carcinoma         | Gefitinib,Erlotinib                              |
|  76 | EGFR:NM_005228:exon21:c.T2573G:p.L858R                          | 0.012 | Lung Non-small Cell Carcinoma         | Gefitinib,Erlotinib                              |
|  77 | EGFR:NM_005228:exon21:c.T2573G:p.L858R                          | 0.012 | Lung Non-small Cell Carcinoma         | Gefitinib                                        |
|  78 | EGFR:NM_005228:exon21:c.T2573G:p.L858R                          | 0.012 | Lung Adenocarcinoma                   | Afatinib                                         |
|  79 | EGFR:NM_005228:exon21:c.T2573G:p.L858R                          | 0.012 | Lung Adenocarcinoma                   | Afatinib                                         |
|  80 | EGFR:NM_005228:exon21:c.T2573G:p.L858R                          | 0.012 | Lung Non-small Cell Carcinoma         | Erlotinib                                        |
|  81 | EGFR:NM_005228:exon21:c.T2573G:p.L858R                          | 0.012 | Lung Non-small Cell Carcinoma         | Afatinib                                         |
|  82 | EGFR:NM_005228:exon21:c.T2573G:p.L858R                          | 0.012 | Lung Adenocarcinoma                   | Afatinib                                         |
|  83 | EGFR:NM_005228:exon21:c.T2573G:p.L858R                          | 0.012 | Lung Non-small Cell Carcinoma         | Gefitinib                                        |
|  84 | EGFR:NM_005228:exon21:c.T2573G:p.L858R                          | 0.012 | Lung Non-small Cell Carcinoma         | Gefitinib                                        |
|  85 | EGFR:NM_005228:exon21:c.T2573G:p.L858R                          | 0.012 | Lung Adenocarcinoma                   | Gefitinib                                        |
|  86 | EGFR:NM_005228:exon21:c.T2573G:p.L858R                          | 0.012 | Lung Non-small Cell Carcinoma         | Lapatinib                                        |
|  87 | EGFR:NM_005228:exon21:c.T2573G:p.L858R                          | 0.012 | Lung Non-small Cell Carcinoma         | Dacomitinib                                      |
|  88 | EGFR:NM_005228:exon21:c.T2573G:p.L858R                          | 0.012 | Lung Non-small Cell Carcinoma         | Neratinib                                        |
|  89 | EGFR:NM_005228:exon21:c.T2573G:p.L858R                          | 0.012 | Lung Non-small Cell Carcinoma         | Afatinib                                         |
|  90 | EGFR:NM_005228:exon21:c.T2573G:p.L858R                          | 0.012 | Lung Non-small Cell Carcinoma         | Canertinib                                       |
|  91 | EGFR:NM_005228:exon21:c.T2573G:p.L858R                          | 0.012 | Lung Non-small Cell Carcinoma         | Erlotinib                                        |
|  92 | EGFR:NM_005228:exon21:c.T2573G:p.L858R                          | 0.012 | Lung Adenocarcinoma                   | Gefitinib                                        |
|  93 | EGFR:NM_005228:exon21:c.T2573G:p.L858R                          | 0.012 | Lung Non-small Cell Carcinoma         | Erlotinib                                        |
|  94 | EGFR:NM_005228:exon21:c.T2573G:p.L858R                          | 0.012 | Lung Non-small Cell Carcinoma         | Afatinib                                         |
|  95 | EGFR:NM_005228:exon21:c.T2573G:p.L858R                          | 0.012 | Cancer                                | Gefitinib,Multikinase Inhibitor AEE788,Erlotinib |
|  96 | EGFR:NM_005228:exon21:c.T2573G:p.L858R                          | 0.012 | Cancer                                | Erlotinib                                        |
|  97 | EGFR:NM_005228:exon21:c.T2573G:p.L858R                          | 0.012 | Lung Non-small Cell Carcinoma         | Erlotinib                                        |
|  98 | EGFR:NM_005228:exon21:c.T2573G:p.L858R                          | 0.012 | Cancer                                | Erlotinib                                        |
|  99 | EGFR:NM_005228:exon21:c.T2573G:p.L858R                          | 0.012 | Lung Non-small Cell Carcinoma         | Erlotinib                                        |
| 100 | EGFR:NM_005228:exon21:c.T2573G:p.L858R                          | 0.012 | Lung Non-small Cell Carcinoma         | Erlotinib                                        |
| 101 | EGFR:NM_005228:exon21:c.T2573G:p.L858R                          | 0.012 | Lung Non-small Cell Carcinoma         | Crizotinib                                       |
| 102 | EGFR:NM_005228:exon21:c.T2573G:p.L858R                          | 0.012 | Lung Adenocarcinoma                   | Erlotinib                                        |
| 103 | EGFR:NM_005228:exon21:c.T2573G:p.L858R                          | 0.012 | Lung Adenocarcinoma                   | Erlotinib                                        |
| 104 | EGFR:NM_005228:exon21:c.T2573G:p.L858R                          | 0.012 | Lung Adenocarcinoma                   | Cetuximab                                        |
| 105 | EGFR:NM_005228:exon21:c.T2573G:p.L858R                          | 0.012 | Lung Small Cell Carcinoma             | Erlotinib                                        |
| 106 | EGFR:NM_005228:exon21:c.T2573G:p.L858R                          | 0.012 | Lung Non-small Cell Carcinoma         | Osimertinib                                      |
| 107 | EGFR:NM_005228:exon21:c.T2573G:p.L858R                          | 0.012 | High Grade Glioma                     | Erlotinib                                        |
| 108 | EGFR:NM_005228:exon21:c.T2573G:p.L858R                          | 0.012 | Lung Non-small Cell Carcinoma         | Dacomitinib                                      |
| 109 | EGFR:NM_005228:exon21:c.T2573G:p.L858R                          | 0.012 | Lung Adenocarcinoma                   | Gefitinib                                        |
| 110 | BRAF:NM_004333:exon15:c.T1799A:p.V600E                          | 0.026 | Melanoma                              | Mirdametinib,Trametinib                          |
| 111 | BRAF:NM_004333:exon15:c.T1799A:p.V600E                          | 0.026 | Colorectal Cancer                     | Sorafenib,Panitumumab                            |
| 112 | BRAF:NM_004333:exon15:c.T1799A:p.V600E                          | 0.026 | Melanoma                              | Vemurafenib                                      |
| 113 | BRAF:NM_004333:exon15:c.T1799A:p.V600E                          | 0.026 | Lung Non-small Cell Carcinoma         | Dabrafenib                                       |
| 114 | BRAF:NM_004333:exon15:c.T1799A:p.V600E                          | 0.026 | Melanoma                              | Dabrafenib,Trametinib                            |
| 115 | BRAF:NM_004333:exon15:c.T1799A:p.V600E                          | 0.026 | Colorectal Cancer                     | Pictilisib Bismesylate,PLX4720                   |
| 116 | BRAF:NM_004333:exon15:c.T1799A:p.V600E                          | 0.026 | Colorectal Cancer                     | Nutlin-3,PLX4720                                 |
| 117 | BRAF:NM_004333:exon15:c.T1799A:p.V600E                          | 0.026 | Colorectal Cancer                     | Bevacizumab,Capecitabine,Vemurafenib             |
| 118 | BRAF:NM_004333:exon15:c.T1799A:p.V600E                          | 0.026 | Colorectal Cancer                     | Vemurafenib                                      |
| 119 | BRAF:NM_004333:exon15:c.T1799A:p.V600E                          | 0.026 | Colorectal Cancer                     | Cetuximab                                        |
| 120 | BRAF:NM_004333:exon15:c.T1799A:p.V600E                          | 0.026 | Melanoma                              | Pictilisib                                       |
| 121 | BRAF:NM_004333:exon15:c.T1799A:p.V600E                          | 0.026 | Colorectal Cancer                     | Panitumumab,Cetuximab                            |
| 122 | BRAF:NM_004333:exon15:c.T1799A:p.V600E                          | 0.026 | Melanoma                              | MEK Inhibitor RO4987655                          |
| 123 | BRAF:NM_004333:exon15:c.T1799A:p.V600E                          | 0.026 | Melanoma                              | Selumetinib,Dactolisib                           |
| 124 | BRAF:NM_004333:exon15:c.T1799A:p.V600E                          | 0.026 | Cancer                                | Cobimetinib                                      |
| 125 | BRAF:NM_004333:exon15:c.T1799A:p.V600E                          | 0.026 | Melanoma                              | Vemurafenib                                      |
| 126 | BRAF:NM_004333:exon15:c.T1799A:p.V600E                          | 0.026 | Colorectal Cancer                     | Vemurafenib                                      |
| 127 | BRAF:NM_004333:exon15:c.T1799A:p.V600E                          | 0.026 | Colorectal Cancer                     | Dabrafenib                                       |
| 128 | BRAF:NM_004333:exon15:c.T1799A:p.V600E                          | 0.026 | Colorectal Cancer                     | Vemurafenib,Gefitinib,Cetuximab                  |
| 129 | BRAF:NM_004333:exon15:c.T1799A:p.V600E                          | 0.026 | Skin Melanoma                         | Vemurafenib                                      |
| 130 | BRAF:NM_004333:exon15:c.T1799A:p.V600E                          | 0.026 | Skin Melanoma                         | Vemurafenib                                      |
| 131 | BRAF:NM_004333:exon15:c.T1799A:p.V600E                          | 0.026 | Colorectal Cancer                     | Panitumumab,Vemurafenib                          |
| 132 | BRAF:NM_004333:exon15:c.T1799A:p.V600E                          | 0.026 | Thyroid Gland Papillary Carcinoma     | Vemurafenib                                      |
| 133 | BRAF:NM_004333:exon15:c.T1799A:p.V600E                          | 0.026 | Melanoma                              | Vemurafenib,Cobimetinib                          |
| 134 | BRAF:NM_004333:exon15:c.T1799A:p.V600E                          | 0.026 | Colorectal Cancer                     | GDC-0879,Dactolisib                              |
| 135 | BRAF:NM_004333:exon15:c.T1799A:p.V600E                          | 0.026 | Gastrointestinal Neuroendocrine Tumor | Vemurafenib,Dabrafenib,Trametinib                |
| 136 | BRAF:NM_004333:exon15:c.T1799A:p.V600E                          | 0.026 | Hairy Cell Leukemia                   | Vemurafenib                                      |
| 137 | BRAF:NM_004333:exon15:c.T1799A:p.V600E                          | 0.026 | Colorectal Cancer                     | Vemurafenib,Panitumumab                          |
| 138 | BRAF:NM_004333:exon15:c.T1799A:p.V600E                          | 0.026 | Thyroid Gland Papillary Carcinoma     | Vemurafenib                                      |
| 139 | BRAF:NM_004333:exon15:c.T1799A:p.V600E                          | 0.026 | Multiple Myeloma                      | Vemurafenib                                      |
| 140 | BRAF:NM_004333:exon15:c.T1799A:p.V600E                          | 0.026 | Multiple Myeloma                      | Vemurafenib                                      |
| 141 | BRAF:NM_004333:exon15:c.T1799A:p.V600E                          | 0.026 | Melanoma                              | Vemurafenib                                      |
| 142 | BRAF:NM_004333:exon15:c.T1799A:p.V600E                          | 0.026 | Colorectal Cancer                     | Irinotecan,Vemurafenib,Cetuximab                 |
| 143 | BRAF:NM_004333:exon15:c.T1799A:p.V600E                          | 0.026 | Colorectal Cancer                     | Panitumumab,Cetuximab                            |
| 144 | BRAF:NM_004333:exon15:c.T1799A:p.V600E                          | 0.026 | Colorectal Cancer                     | Oxaliplatin                                      |
| 145 | BRAF:NM_004333:exon15:c.T1799A:p.V600E                          | 0.026 | Colorectal Cancer                     | Irinotecan                                       |
| 146 | BRAF:NM_004333:exon15:c.T1799A:p.V600E                          | 0.026 | Colorectal Cancer                     | Capecitabine,Oxaliplatin,Bevacizumab             |
| 147 | BRAF:NM_004333:exon15:c.T1799A:p.V600E                          | 0.026 | Melanoma                              | Trametinib                                       |
| 148 | BRAF:NM_004333:exon15:c.T1799A:p.V600E                          | 0.026 | Lung Non-small Cell Carcinoma         | Trametinib,Dabrafenib                            |
| 149 | BRAF:NM_004333:exon15:c.T1799A:p.V600E                          | 0.026 | Colorectal Cancer                     | Cetuximab,FOLFOX-4 Regimen                       |
| 150 | BRAF:NM_004333:exon15:c.T1799A:p.V600E                          | 0.026 | Melanoma                              | Vemurafenib                                      |
| 151 | BRAF:NM_004333:exon15:c.T1799A:p.V600E                          | 0.026 | Melanoma                              | Vemurafenib                                      |
| 152 | BRAF:NM_004333:exon15:c.T1799A:p.V600E                          | 0.026 | Melanoma                              | Vemurafenib                                      |
| 153 | BRAF:NM_004333:exon15:c.T1799A:p.V600E                          | 0.026 | Skin Melanoma                         | Trametinib,Dabrafenib                            |
| 154 | BRAF:NM_004333:exon15:c.T1799A:p.V600E                          | 0.026 | Childhood Pilocytic Astrocytoma       | Vemurafenib                                      |
| 155 | BRAF:NM_004333:exon15:c.T1799A:p.V600E                          | 0.026 | Ovarian Serous Carcinoma              | Vemurafenib                                      |
| 156 | BRAF:NM_004333:exon15:c.T1799A:p.V600E                          | 0.026 | Colorectal Cancer                     | Panitumumab                                      |
| 157 | BRAF:NM_004333:exon15:c.T1799A:p.V600E                          | 0.026 | Cholangiocarcinoma                    | Dabrafenib,Trametinib                            |
| 158 | BRAF:NM_004333:exon15:c.T1799A:p.V600E                          | 0.026 | Intrahepatic Cholangiocarcinoma       | Trametinib,Dabrafenib                            |
| 159 | BRAF:NM_004333:exon15:c.T1799A:p.V600E                          | 0.026 | Intrahepatic Cholangiocarcinoma       | Dabrafenib,Trametinib                            |
| 160 | BRAF:NM_004333:exon15:c.T1799A:p.V600E                          | 0.026 | Cholangiocarcinoma                    | Panitumumab,Vemurafenib,Irinotecan               |
| 161 | BRAF:NM_004333:exon15:c.T1799A:p.V600E                          | 0.026 | Lung Non-small Cell Carcinoma         | Vemurafenib                                      |
| 162 | BRAF:NM_004333:exon15:c.T1799A:p.V600E                          | 0.026 | Ovarian Cancer                        | Vemurafenib                                      |
| 163 | BRAF:NM_004333:exon15:c.T1799A:p.V600E                          | 0.026 | Colorectal Cancer                     | Vemurafenib                                      |
| 164 | BRAF:NM_004333:exon15:c.T1799A:p.V600E                          | 0.026 | Thyroid Gland Anaplastic Carcinoma    | Pertuzumab,Vemurafenib                           |
| 165 | BRAF:NM_004333:exon15:c.T1799A:p.V600E                          | 0.026 | Laryngeal Squamous Cell Carcinoma     | Vemurafenib                                      |
| 166 | BRAF:NM_004333:exon15:c.T1799A:p.V600E                          | 0.026 | Thyroid Gland Anaplastic Carcinoma    | Vemurafenib                                      |
| 167 | BRAF:NM_004333:exon15:c.T1799A:p.V600E                          | 0.026 | Colorectal Cancer                     | Panitumumab,Trametinib,Dabrafenib                |
| 168 | BRAF:NM_004333:exon15:c.T1799A:p.V600E                          | 0.026 | Colorectal Adenocarcinoma             | Trametinib,Panitumumab                           |
| 169 | BRAF:NM_004333:exon15:c.T1799A:p.V600E                          | 0.026 | Melanoma                              | Dabrafenib,Trametinib                            |
| 170 | BRAF:NM_004333:exon15:c.T1799A:p.V600E                          | 0.026 | Melanoma                              | Vemurafenib,Dabrafenib                           |
| 171 | BRAF:NM_004333:exon15:c.T1799A:p.V600E                          | 0.026 | Melanoma                              | Dabrafenib,Trametinib                            |
| 172 | BRAF:NM_004333:exon15:c.T1799A:p.V600E                          | 0.026 | Melanoma                              | Trametinib,Dabrafenib                            |
| 173 | BRAF:NM_004333:exon15:c.T1799A:p.V600E                          | 0.026 | Thyroid Gland Anaplastic Carcinoma    | Trametinib,Dabrafenib                            |
| 174 | BRAF:NM_004333:exon15:c.T1799A:p.V600E                          | 0.026 | Colorectal Cancer                     | Cetuximab,Encorafenib,Binimetinib                |
| 175 | BRAF:NM_004333:exon15:c.T1799A:p.V600E                          | 0.026 | Biliary Tract Cancer                  | Dabrafenib,Trametinib                            |
| 176 | BRAF:NM_004333:exon15:c.T1799A:p.V600E                          | 0.026 | Langerhans Cell Sarcoma               | Vemurafenib                                      |
| 177 | BRAF:NM_004333:exon15:c.T1799A:p.V600E                          | 0.026 | Colorectal Cancer                     | Binimetinib,Cetuximab,Encorafenib                |
| 178 | BRAF:NM_004333:exon15:c.T1799A:p.V600E                          | 0.026 | Colorectal Cancer                     | Irinotecan,Cetuximab,Vemurafenib                 |
| 179 | BRAF:NM_004333:exon15:c.T1799A:p.V600E                          | 0.026 | Colorectal Cancer                     | Vemurafenib,Erlotinib                            |
| 180 | BRAF:NM_004333:exon15:c.T1799A:p.V600E                          | 0.026 | Thyroid Gland Papillary Carcinoma     | Vemurafenib                                      |
| 181 | BRAF:NM_004333:exon15:c.T1799A:p.V600E                          | 0.026 | Colorectal Cancer                     | Encorafenib,Cetuximab                            |
| 182 | KRAS:NM_004985:exon4:c.G436A:p.A146T                            | 0.015 | Colorectal Cancer                     | Selumetinib,Dactolisib                           |
| 183 | KRAS:NM_004985:exon4:c.G436A:p.A146T                            | 0.015 | Colorectal Cancer                     | Cetuximab                                        |
| 184 | KRAS:NM_004985:exon4:c.G436A:p.A146T                            | 0.015 | Colorectal Cancer                     | FOLFOX-4 Regimen,Cetuximab                       |
| 185 | KRAS:NM_004985:exon2:c.G38A:p.G13D                              | 0.017 | Colorectal Cancer                     | Cetuximab                                        |
| 186 | KRAS:NM_004985:exon2:c.G38A:p.G13D                              | 0.017 | Colorectal Cancer                     | Cetuximab                                        |
| 187 | KRAS:NM_004985:exon2:c.G38A:p.G13D                              | 0.017 | Colorectal Cancer                     | Cetuximab                                        |
| 188 | KRAS:NM_004985:exon2:c.G38A:p.G13D                              | 0.017 | Colorectal Cancer                     | Cetuximab                                        |
| 189 | KRAS:NM_004985:exon2:c.G38A:p.G13D                              | 0.017 | Colorectal Cancer                     | Cetuximab                                        |
| 190 | KRAS:NM_004985:exon2:c.G38A:p.G13D                              | 0.017 | Breast Cancer                         | Pictilisib                                       |
| 191 | KRAS:NM_004985:exon2:c.G38A:p.G13D                              | 0.017 | Colorectal Cancer                     | Panitumumab                                      |
| 192 | KRAS:NM_004985:exon2:c.G38A:p.G13D                              | 0.017 | Colorectal Cancer                     | Dactolisib,Selumetinib                           |
| 193 | KRAS:NM_004985:exon2:c.G38A:p.G13D                              | 0.017 | Colorectal Cancer                     | Cetuximab                                        |
| 194 | KRAS:NM_004985:exon2:c.G38A:p.G13D                              | 0.017 | Colorectal Cancer                     | Cetuximab                                        |
| 195 | KRAS:NM_004985:exon2:c.G38A:p.G13D                              | 0.017 | Colorectal Cancer                     | Cetuximab                                        |
| 196 | KRAS:NM_004985:exon2:c.G38A:p.G13D                              | 0.017 | Colorectal Cancer                     | Regorafenib                                      |
| 197 | KRAS:NM_004985:exon2:c.G38A:p.G13D                              | 0.017 | Colorectal Cancer                     | Panitumumab,Cetuximab                            |
| 198 | KRAS:NM_004985:exon2:c.G38A:p.G13D                              | 0.017 | Colorectal Cancer                     | Panitumumab,Cetuximab                            |
| 199 | KRAS:NM_004985:exon2:c.G35A:p.G12D                              | 0.019 | Lung Non-small Cell Carcinoma         | Selumetinib,Dactolisib                           |
| 200 | KRAS:NM_004985:exon2:c.G35A:p.G12D                              | 0.019 | Pancreatic Carcinoma                  | Akt Inhibitor MK2206                             |
| 201 | KRAS:NM_004985:exon2:c.G35A:p.G12D                              | 0.019 | Hairy Cell Leukemia                   | Vemurafenib                                      |
| 202 | KRAS:NM_004985:exon2:c.G35A:p.G12D                              | 0.019 | Colorectal Cancer                     | Therapeutic Tumor Infiltrating Lymphocytes       |
| 203 | KRAS:NM_004985:exon2:c.G35A:p.G12D                              | 0.019 | Colorectal Cancer                     | Panitumumab                                      |
| 204 | KRAS:NM_004985:exon2:c.G35A:p.G12D                              | 0.019 | Colorectal Cancer                     | Cetuximab                                        |
| 205 | KRAS:NM_004985:exon2:c.G35A:p.G12D                              | 0.019 | Colorectal Cancer                     | Selumetinib,Dactolisib                           |
| 206 | KRAS:NM_004985:exon2:c.G35A:p.G12D                              | 0.019 | Colorectal Cancer                     | Panitumumab                                      |
| 207 | KRAS:NM_004985:exon2:c.G35A:p.G12D                              | 0.019 | Lung Cancer                           | Gefitinib                                        |
| 208 | KRAS:NM_004985:exon2:c.G35A:p.G12D                              | 0.019 | Multiple Myeloma                      | Melphalan                                        |
| 209 | KRAS:NM_004985:exon2:c.G35A:p.G12D                              | 0.019 | Multiple Myeloma                      | Melphalan                                        |
| 210 | KRAS:NM_004985:exon2:c.G35A:p.G12D                              | 0.019 | Multiple Myeloma                      | Melphalan                                        |
| 211 | KRAS:NM_004985:exon2:c.G35A:p.G12D                              | 0.019 | Multiple Myeloma                      | Melphalan                                        |
| 212 | KRAS:NM_004985:exon2:c.G35A:p.G12D                              | 0.019 | Colorectal Cancer                     | Regorafenib                                      |
| 213 | KRAS:NM_004985:exon2:c.G35A:p.G12D                              | 0.019 | Melanoma                              | Vemurafenib                                      |
| 214 | KRAS:NM_004985:exon2:c.G35A:p.G12D                              | 0.019 | Ovarian Cancer                        | Cetuximab                                        |
| 215 | KRAS:NM_004985:exon2:c.G35A:p.G12D                              | 0.019 | Colorectal Cancer                     | Panitumumab,Cetuximab                            |
| 216 | MAP2K1:NM_002755:exon2:c.A167C:p.Q56P                           | 0.068 | Melanoma                              | Selumetinib                                      |